WO2009017460A1 - Method for identifying and selecting cardiomyocytes - Google Patents

Method for identifying and selecting cardiomyocytes Download PDF

Info

Publication number
WO2009017460A1
WO2009017460A1 PCT/SG2007/000226 SG2007000226W WO2009017460A1 WO 2009017460 A1 WO2009017460 A1 WO 2009017460A1 SG 2007000226 W SG2007000226 W SG 2007000226W WO 2009017460 A1 WO2009017460 A1 WO 2009017460A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cardiomyocytes
cardiomyocyte
population
stem cells
Prior art date
Application number
PCT/SG2007/000226
Other languages
French (fr)
Other versions
WO2009017460A8 (en
Inventor
William L. Rust
Thavamalar Balakrishnan
Original Assignee
Es Cell International Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Es Cell International Pte Ltd filed Critical Es Cell International Pte Ltd
Priority to PCT/SG2007/000226 priority Critical patent/WO2009017460A1/en
Priority to US12/671,274 priority patent/US20100247493A1/en
Priority to AU2007357127A priority patent/AU2007357127B2/en
Priority to GB1002084.0A priority patent/GB2465502B/en
Publication of WO2009017460A1 publication Critical patent/WO2009017460A1/en
Publication of WO2009017460A8 publication Critical patent/WO2009017460A8/en
Priority to IL203575A priority patent/IL203575A/en
Priority to US14/958,923 priority patent/US20160320409A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Definitions

  • the present invention relates to the identification and isolation of cardiomyocytes from human embryonic stem (hES) cells.
  • Cardiovascular diseases remain the leading cause of mortality and morbidity world wide. Since adult cardiomyocytes do not regenerate, the death of these cells compromises the myocardial contractile function. For instance when the coronary vessel is occluded by a thrombus and the surrounding cardiomyocytes cannot be supplied with necessary energy sources from other coronary vessels. The loss of functional cardiomyocytes may lead to chronic heart failure. A potential route of restoring normal heart function is replacement of injured and dead cardiomyocytes by new functional cardiomyocytes.
  • Cardiomyocytes have the potential to restore heart function after myocardial infarction or heart failure and human embryonic stem (hES) cells are potential source of transplantable cardiomyocytes (Siu et al, 2007).
  • cardiomyocytes A limitation in the study of cardiomyocytes has been the inability to identify these cells prospectively.
  • the current protocols designed to direct the differentiation of human embryonic stem cells in vitro towards cells of the " cardiomyocyte lineage produce a heterogeneous population of cells of various identity and developmental stage.
  • pure or relatively pure cardiomyocyte populations are desired.
  • Nearly pure populations of cardiomyocytes have been generated from mouse embryonic stem cells using a method requiring prior genetic transformation of the stem cells. Genetic transformation of stem cells is time consuming and may preclude the enriched cell population from use in the clinic. It would therefore be an advantage to have a method capable of isolating a population of differentiated cells enriched for cardiomyocytes from wild-type stem cells.
  • a large proportion of the enriched cardiomyocytes were viable and capable of proliferation, allowing the enriched population to expand in culture for a number of population doublings.
  • the present invention addresses the problems above and in particular provides new and improved method of identification and isolation of cardiomyocytes from differentiated embryonic stem (ES) cells.
  • ES embryonic stem
  • the present invention provides a method of identifying and selecting a cardiomyocyte population from a heterogeneous population of differentiated stem cells, comprising contacting the heterogeneous cell population with at least one agent that specifically binds to at least one cardiomyocyte marker and selecting the bound cells as cardiomyocytes.
  • the method further comprises isolating the selected cardiomyocyte population.
  • the at least one cardiomyocyte marker is selected from a group consisting of CD166 (ALCAM), VEGF receptor FIkI , N- cadherin, CD133 and CD117 (C-kit). More in particular the at least one cardiomyocyte marker is CD166 (ALCAM).
  • the at least one cardiomyocyte marker may be a fetal marker.
  • the identified cells may comprise at least 50% cardiomyocytes.
  • the identified cardiomyocytes may have a fetal phenotype.
  • cardiomyocytes may be capable of proliferating in culture.
  • the identified cardiomyocytes may be in S phase of the cell cycle. More in particular the identified cardiomyocytes are capable of rhythmic contractions and/or forming electrically coupled cell clusters.
  • the stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoietic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells.
  • ES embryonic stem
  • pluripotent stem cells pluripotent stem cells
  • hematopoietic stem cells hematopoietic stem cells
  • totipotent stem cells mesenchymal stem cells
  • neural stem cells and adult stem cells.
  • the stem cells may be human ES cells.
  • the invention provides a cardiomyocyte population having the characteristics as herein defined.
  • a cardiomyocyte population identified and /or isolated by the method according to the present invention.
  • a cardiomyocyte population isolated according to the method of the present invention.
  • the invention provides a model for study of human cardiomyocytes in culture, comprising the cardiomyocyte population.
  • the invention further provides a kit for cardiotoxic testing comprising the cardiomyocyte population.
  • Another aspect of the invention includes a method of preventing, repairing and/or treating at least one cardiac disorder in a subject, the said method comprising transplanting the isolated cardiomyocyte population.
  • the cardiac disorder may be selected from a group consisting of myocardial infarction, cardiomyopathy, congestive heart failure, ventricular septal defect, atria septal defect, congenital heart defect and ventricular aneurysm.
  • the invention provides a model for testing suitability of cardiomyocytes for cardiac transplantation, said model comprising: A non-human animal having a measurable parameter of cardiac function wherein the said animal is capable of receiving an isolated cardiomyocyte population; and a means to determine cardiac function of the animal before and after transplantation of the isolated cardiomyocyte population.
  • the model may be an immunodeficient animal created as a model of cardiac muscle degeneration following infarct that is used as a universal acceptor of the isolated cardiomyocyte population. More in particular the animal model may be murine, ovine, bovine, porcine or a non-human primate. More in particular the parameter of cardiac function may be contractile function.
  • the invention provides a method of screening for cardiovascular compounds.
  • the method may comprise subjecting the said cardiomyocyte population to at least one test compound, and observing a cardiac specific response of the card io myocytes to at least one test compound.
  • the cardiac specific response may comprise alteration of Q-T wave.
  • Figure 1 represents the expression of the cardiac transcription factor Nkx2.5 analysed by immunofluorescence following culturing of human embryonic stem cells for 14 days, under conditions which promote cardiomyocyte differentiation. The nuclei are counterstained with DAPI (blue), the area shown by arrows.
  • Figure 1A represents the co-localization of Nkx2.5 (green) with the cardiac marker ⁇ MHC (red).
  • the black and white view of Figure 1A represents the co- localization of Nkx2.5 (dark white) with the cardiac marker ⁇ MHC (light grey)
  • Figure 1 B represents the co-localization of Nkx2.5 (red) with the cardiac marker MLC2a (green).
  • Figure 1 B represents the co- localization of Nkx2.5 (light grey) with the cardiac marker MLC2a (dark white).
  • Figure 1C represents the co-localization of Nkx2.5 (red) with the cardiac marker alpha-actinin (green).
  • the black and white view of Figure 1C represents the co- localization of Nkx2.5 (light grey) with the cardiac marker alpha-actinin (dark white).
  • Figure 1 D represents the co-localization of Nkx2.5 (red) with the cardiac marker tropomyosin (green).
  • the black and white view of Figure 1 D represents the co- localization of Nkx2.5 (light grey) with the cardiac marker tropomyosin (dark white).
  • Figure 1E represents the co-localization of Nkx2.5 (red) with the cardiac marker MLC2v (green).
  • the black and white view of Figure 1 E represents the co- localization of Nkx2.5 (light grey) with the cardiac marker MLC2v (dark white).
  • Figure 2 represents the expression of the cardiac transcription factor Nkx2.5 (green) analysed by immunofluorescence following culturing of human embryonic stem cells for 14 days under conditions which promote cardiomyocyte differentiation. The nuclei are counterstained with DAPI (blue), the area shown by arrows.
  • Figure 2A represents the co-localization of Nkx2.5 (green) with the cardiac marker CD166 (red).
  • the black and white view of Figure 2A represents the co-localization of Nkx2.5 (dark white) with the cardiac marker CD166 (light grey).
  • Figure 2B represents the co-localization of Nkx2.5 (green) with the cardiac marker Flk-1 (red).
  • the black and white view of Figure 2B represents the co-localization of Nkx2.5 (dark white) with the cardiac marker Flk-1 (light grey).
  • Figure 2C represents the co-localization of Nkx2.5 (green) with the cardiac marker N-cadherin (red).
  • the black and white view of Figure 2C represents the co-localization of Nkx2.5 (dark white) with the cardiac marker N-cadherin (light grey).
  • Figure 4 represents quantitative PCR analysis of RNA extracted from MACS sorted cells based on expression of CD166.
  • Figure represents the expression of the cardiac markers Nkx2.5 and ⁇ MHC, neural marker NeuroDI , pluripotent cells marker Oct4 and endodermal cells marker AFP on cells isolated based on expression of CD166 enriched for cardiomyocytes.
  • Figure 5 represents proliferation of cells in collagen I coated culture dishes .isolated based on expression of CD166..
  • Figure 5A represents the sub-confluent layer of surviving cells attached to the dish after one day in culture.
  • Figure 5B represents confluent layer of surviving cells attached to the dish after six days in culture.
  • Figure 5C represents the analysis of cells in S phase by BrdU (green) incorporation into the layer of surviving cells attached to the dish after two days in culture.
  • Black and white view of Figure 5C represents the analysis of cells in S phase by BrdU (dark grey) incorporation into the layer of surviving cells attached to the dish after two days in culture
  • Figure 6 represents immunofluorescence analysis of the expression of Nkx2.5 (dark pink) and MLC2a (green) following the sorting of the 14 day old EBs based on expression of CD166, and plated on collagen I coated dishes in medium containing bovine serum and allowed to grow to confluence over a period of five days. Nuclei are counterstained with DAPI (blue). In the black and white view the Nk2.5 stained cells appear to be dark white while the DAPI counterstain appear as light grey.
  • Figure 6A represents CD166+ cells expressing the cardiomyocyte marker Nkx2.5 (dark pink). The black and white view of Figure 6A represents CD166+ cells expressing the cardiomyocyte marker Nkx2.5 (dark white).
  • Figure 6B represents that CD166- cells do not express or express very little of the cardiomyocyte marker Nkx2.5 (dark pink).
  • the black and white view Figure 6B represents that CD166- cells do not express or express very little of the cardiomyocyte marker Nkx2.5 (dark white)
  • Figure 6C represents CD166+ cells expressing the cardiomyocyte markers Nkx2.5 (dark pink) and MLC2a (green).
  • the black and white view Figure 6C represents CD166+ cells expressing the cardiomyocyte markers Nkx2.5 (dark white) and MLC2a (grey).
  • SEQ ID NO. 1 refers to Actin forward primer 5'- CAATGTGGCCGAGGACTTTG -3'
  • SEQ ID NO. 2 refers to Actin reverse primer
  • 5'- AGAAGACAGAGGCGGACAAC -3' SEQ ID NO. 4 refers to Nkx2.5 reverse primer
  • 5'- CGCCGCTCCAGTTCACAG -3' SEQ ID NO. 5 refers to ⁇ MHC forward primer
  • SEQ ID NO. 6 refers to ⁇ MHC reverse primer 5'- CGCTCCTTGAGGTTGAAAAG -3'
  • SEQ ID NO. 7 refers to NeuroD forward primer
  • 5'- GCCCCAGGGTTATGAGACTA -3' SEQ ID NO. 8 refers to NeuroD reverse primer
  • 5'- GTCCAGCTTGGAGGACCTT -3' SEQ ID NO. 9 refers to Oct4 forward primer
  • SEQ ID NO. 10 refers to Oct4 reverse primer
  • 5'- GCCGGTTACAGAACCACACT -3' SEQ ID NO. 11 refers to AFP forward primer
  • 5'- GTAGCGCTGCAAACAATGAA -3' SEQ ID NO. 12 refers to AFP reverse primer
  • the present invention provides new and/or improved method of identification and isolation of cardiomyocytes from differentiated embryonic stem (ES) cells.
  • ES embryonic stem
  • the invention provides a method of identifying and selecting a cardiomyocyte population from a heterogeneous population of differentiated stem cells, comprising contacting the heterogeneous cell population with at least one agent that specifically binds to at least one cardiomyocyte marker and selecting cells bound to the said agent as cardiomyocytes.
  • the heterogeneous population of differentiated stem cells may be prepared according to the method described in WO 2007/030870 (the content of which is herein incorporated by reference).
  • the method further comprises isolating the selected cardiomyocyte population.
  • the at least one cardiomyocyte marker is selected from the group consisting of CD166 (ALCAM), VEGF receptor FIkI , N- cadherin, CD133 and CD117 (C-kit). More in particular the at least one cardiomyocyte marker is CD166 (ALCAM).
  • the at least one cardiomyocyte marker may be a fetal marker.
  • Sorting of cells based on surface marker expression may be accomplished by using any technology known in the art. For example, sorting of cells based on surface marker expression may be accomplished by using Flow Assisted Cell Sorting (FACS) or Automated Magnetic Cell Sorting (MACS) technology.
  • FACS Flow Assisted Cell Sorting
  • MACS Automated Magnetic Cell Sorting
  • the preparation of the cells for FACS is similar to preparation of cells for MACS except that the secondary antibody is conjugated to a FACS-compatible fluorophore instead of a magnetic microbead.
  • At least 50% of the identified, selected and/or isolated cells according to the invention may comprise cardiomyocytes.
  • 55%, 60%, 70%, 80% or 90% of the isolated cells may comprise cardiomyocytes.
  • the identified, selected and/or isolated cardiomyocytes may have a fetal phenotype.
  • the cardiomyocytes may be capable of proliferating in culture. In particular at least 25% of the identified cardiomyocytes may be in S phase of the cell cycle. More in particular, the identified cardiomyocytes are capable of rhythmic contractions and/or forming electrically coupled cell clusters.
  • the stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoitic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells.
  • ES embryonic stem
  • the stem cells may be human ES cells.
  • the stem cells may be isolated ES cells.
  • the ES cell may be obtained from at least one ES cell line recognised the NIH human stem cell registry (http://stemcells.nih.gov/research/registry/defaultpage.asp) according to the methods and ethical standards mentioned therein. More in particular, the hES cell line hES3 from ES Cell International may be used.
  • stem cells refers to a stem cell that is undifferentiated prior to culturing and is capable of undergoing differentiation.
  • the stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoietic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells.
  • ES embryonic stem
  • pluripotent stem cells pluripotent stem cells
  • hematopoietic stem cells hematopoietic stem cells
  • totipotent stem cells mesenchymal stem cells
  • neural stem cells neural stem cells
  • adult stem cells e.g., the stem cell may be human embryonic stem (hES) cells.
  • hES human embryonic stem
  • the stem cell may be derived from a cell culture, such as hES cells.
  • the stem call may be derived from an embryonic cell line or embryonic tissue.
  • the embryonic stem cells may be cells which have been cultured and maintained in an undifferentiated
  • the stem cells suitable for use in the present methods may be derived from a patient's own tissue. This would enhance compatibility of differentiated tissue grafts derived from stem cells with the patient.
  • Differentiated stem cells may express markers on their cell surface that may be indicative of a specific cell type, for example indicative of cardiomyocytes.
  • the markers may be used to identify and isolate the differentiated cardiomyocytes from other differentiated cells and undifferentiated stem cells.
  • Markers are polypeptide molecules that are expressed on a cell of interest.
  • the specific marker may be present only in the cells of interest, or encompass the cells of interest, or detectable level of the marker is sufficiently higher in the cells of interest, compared to other cells, such that the cells of interest can be identified, using any of a variety of methods as known in the art. It will be understood by those of skill in the art that expression is a relative term, and the expression will vary from other cell types.
  • a progenitor cell may express a polypeptide that is not found in the fully differentiated progeny cell.
  • a cell of interest may express a polypeptide that is not expressed in surrounding tissues, e.g.
  • the cardiomyocyte cells of fetal phenotype may express CD166 polypeptides not found in mature cardiomyocytes or on other cells of a non- cardiomyocyte lineage. This specificity is sufficient for purposes of cell identification and isolation. Therefore, "fetal markers” as used herein refer to a marker on a cell, in particular cardiomyocytes that is indicative of the fetal phenotype of the cells. Fetal phenotype further refers to cells that are capable of proliferating in culture.
  • fetal markers of interest in the present invention include CD166 (ALCAM), VEGF receptor FIkI 1 N-cadherin, CD133, CD117 (C- kit), Nkx2.5, ⁇ -MHC, MLC2a, MLC2v, ⁇ -actinin and tropomyosin.
  • fetal markers of interest in the present invention include CD166 (ALCAM), VEGF receptor Flk1 , N-cadherin, CD133, CD117 (C-kit).
  • the cardiomyocyte marker may be CD166 (ALCAM).
  • a heterogeneous population of differentiated stem cell is contacted with at least one a marker-specific "agent", and detecting directly or indirectly the presence of the complex formed.
  • agent refers to a molecule capable of binding to another molecule, for example the marker on the cell surface, through chemical or physical means, wherein the agent and the marker form a binding pair.
  • antibodies specific for these cell surface markers are commercially available, or may be produced using conventional methods as known in the art, therefore the antibodies and markers form a binding pair.
  • affinity reagents are conjugated with a label for use in separation.
  • Labels include magnetic beads, which allow for direct separation on magnetic assisted cell sorter (MACS), biotin, which can be removed with avidin or streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter (FACS), or the like, to allow for ease of separation of the particular cell type.
  • Fluorochromes that find use include phycobiliproteins, e.g. phycoerythrin and allophycocyanins, fluorescein and Texas red. Frequently each antibody is labeled with a different fluorochrome, to permit independent analysis or sorting for each marker.
  • the invention provides methods of preventing, repairing and/or treating at least one cardiac disorder in a subject, the method comprising transplanting the cardiomyocyte population in a subject.
  • the subject is, in particular, a subject in need of the treatment thereof.
  • the disorder as, used herein include but are not limited to myocardial infarction, cardiomyopathy, congestive heart failure, ventricular septal defect, atria septal defect, congenital heart defect and ventricular aneurysm.
  • the method includes introducing a cardiomyocyte population of the invention into cardiac tissue of a subject.
  • the isolated cardiomyocyte population is transplanted into damaged cardiac tissue of the subject. More in particular the method results in the restoration of cardiac function in a subject.
  • the cardiomyocyte population may resemble a human fetal atrial cell in culture.
  • the cardiomyocyte population may resemble a human fetal pacemaker cell in culture.
  • the cardiomyocyte population may comprise plurality of isolated cardiomyocytes wherein the cardiomyocytes may be coupled.
  • the coupling may be, for example, through gap junctions and/or adherens junctions, wherein the coupling is electrical.
  • the subject may be a human or non-human animal.
  • the present invention also provides at least one cardiomyocyte population identified, selected and/or isolated according to the method of the present invention for use in medicine. In particular, in preventing, repairing and/or treating at least one cardiac disorder in a subject. There is also provided the use of at least one cardiomyocyte population identified, selected and/or isolated according to the method of the present invention for the preparation of a medicament in preventing, repairing and/or treating at least one cardiac disorder in a subject.
  • the present invention also provides a cardiac model for testing the ability of the isolated cardiomyocyte population to restore cardiomyocyte function.
  • a cardiac model for testing the ability of the isolated cardiomyocyte population to restore cardiomyocyte function.
  • a host animal such as, but not limited to, an immunodeficient mouse may be used as a 'universal acceptor' of cardiomyocytes produced by the methods of the present invention.
  • the myocardial model of the present invention is designed to assess the extent of cardiac repair following transplant of cardiomyocytes into the host animal.
  • the host animal may be an immunodeficient animal created as a model of cardiac muscle degeneration following infarct that is used as a universal acceptor of isolated cardiomyocytes.
  • the non-human animal may be any species including but not limited to murine, ovine, canine, bovine, porcine and any non-human primates. Parameters used to measure cardiac repair in these animals may include, but are not limited to, electrophysiological characteristic of heart tissue or various heart functions. For instance, contractile function may be assessed in terms of volume and pressure changes in a heart. Methods of assessing heart function and cardiac tissue characteristics may also involve techniques known to person skilled in the art.
  • the invention further provides cardiomyocytes produced using the methods of the current invention that may be used for transplantation, cell therapy or gene therapy.
  • the invention provides the use of cardiomyocytes produced using the methods of the current invention, in a cardiac model for testing the ability to restore cardiac function. More in particular the invention provides the use of cardiomyocytes in a cardiac model designed to assess the extent of cardiac repair following transplant of cardiomyocytes into a suitable host animal.
  • the present invention also provides a model for study of human cardiomyocytes in culture, comprising the cardiomyocytes isolated by the method of the current invention.
  • This model may be used in the development of cardiomyocyte transplantation therapies.
  • the invention provides a method of screening for cardiovascular compounds.
  • the method may comprise subjecting the said cardiomyocyte population to at least one test compound, and observing a cardiac specific response of the cardiomyocytes to at least one test compound.
  • the specific cardiac response may be monitored by the changes of beat frequency, amplitude and/or duration of the cardiomyocyte(s) to at least one test compound. More in particular the cardiac specific response may comprise alteration of Q-T wave.
  • kits for cardiotoxic testing or for screening of cardiovascular compound(s) comprising at least one cardiomyocyte population according to the invention.
  • a kit for preventing, repairing and/or treating at least one cardiac disorder in a subject comprising at least one cardiomyocyte population according to the invention.
  • the kit may further comprise instructions for use.
  • hES cells were passaged by treatment with collagenase I (however, collagenase IV may also be used) (Gibco) for 3 minutes followed by mechanical dissociation. Harvested cells were transferred to newly prepared feeder cells.
  • the pluripotent hES grown on human feeders in 10cm dishes were rinsed with phosphate buffered saline (PBS). PBS was then replaced by fresh stem cell maintenance medium.
  • the dish was scored using a pipette tip such that each colony was divided approximately in two cell clusters.
  • Cell clusters were scraped from the substrate and transferred to a conical tube. The cell clusters were allowed to settle to the bottom of the conical tube and the media was aspirated. The media was replaced by fresh stem cell maintenance medium.
  • the cell clusters were transferred to plastic dishes to discourage cell attachment (Ultra-low attach dishes, Costar). The dishes were incubated in the tissue culture incubators for a period of 24 hours.
  • EBs embryoid bodies
  • the dishes were tilted such that the embryoid bodies sank to the bottom and the media was aspirated.
  • the medium was replaced by defined basic serum free (bSFS) medium comprising DMEM supplemented with 1x MEM non-essential amino acids (Invitrogen), 2mM L-Glutamine (Invitrogen), 0.0055 mg/ml Transferrin (Roche), 5 ng/ml sodium Selenite (Sigma), 0.1 mM beta-mercaptoethanol, with or without Penicillin/Streptomycin (Invitrogen). which promotes cardiomyocyte differentiation as described in WO 2007/030870.
  • bSFS basic serum free
  • EBs were transferred to a conical tube and allowed to settle.
  • the medium was aspirated and the EBs rinsed with PBS not containing either magnesium or calcium.
  • EBs were incubated at 37°C in either undiluted Accumax reagent (Innovative Cell Technologies), or a 0.25 or 0.005% solution of trypsin (Roche) in phosphate buffered saline.
  • the enzymatic reactions were arrested by the addition of differentiation medium containing 20% fetal calf serum. Residual clusters of cells were removed by passing the cell suspension through a filter with maximum pore size of 40 ⁇ m.
  • the single cell suspensions were pelleted in a centrifuge refrigerated to 4 0 C at approximately 300 gravities for 15 minutes.
  • the cell pellet was resuspended in an immunoglobulin blocking buffer (FcR blocking buffer, Miltenyi Biotec) at a concentration of 1X10 6 cells per 100 ⁇ l.
  • FcR blocking buffer Miltenyi Biotec
  • a concentration of 0.5 to 5 ⁇ g/ml of antibody mouse monoclonal ab23829, Abeam
  • the cell suspension was incubated for 30 minutes at 4 0 C while rocking.
  • the cells were pelleted again in a refrigerated centrifuge at approximately 300 gravities for 10 minutes.
  • the blocking buffer containing the anti-CD166 antibody was aspirated and replaced by 8OuI per 1X10 6 cells supplemented with 20ul of magnetic microbead conjugated antibody which recognizes the anti-CD166 antibody (rat anti-mouse igG2a+b microbeads, 472-01 Miltenyi Biotec) and was incubated for 30 minutes at 4°C while rocking. The cells were pelleted and resuspended in fresh blocking buffer. Cells bound to magnetic microbeads were separated from the unbound cell population by being passed through a column held in a strong magnetic field (Miltenyi Biotec columns, Miltenyi Biotec magnetic holder).
  • the sorted cells were pelleted, resuspended in bSFS media containing 5 ⁇ M SB203580 and 20% fetal calf serum and plated in tissue culture dishes pre-coated with 100 ⁇ g/ml of collagen I (Roche). The media was changed every 2-3 days. After the cultures had grown to confluence, the medium was replaced by bSFS medium containing 5 ⁇ M SB203580 but without fetal calf serum.
  • Primers comprising the sequence of SEQ ID NO:1 and SEQ ID NO:2 were used to detect binding amplification of the actin sequence
  • primers comprising the sequence of SEQ ID NO: 3 and SEQ ID NO:4 were used to detect Nkx2.5
  • primers comprising the sequence of SEQ ID NO:5 and SEQ ID NO:6 were used to detect ⁇ MHC sequence
  • primers comprising the sequence of SEQ ID NO: 7 and SEQ ID NO: 8 were used to NeuroD
  • primers comprising the sequence of SEQ ID NO. 9 and SEQ ID NO: 10 were used to amplify oct4 sequence
  • primers comprising the sequence of SEQ ID NO. 11 and SEQ ID NO: 12 were used to amplify AFP sequence. Expression was calculated based on a standard curve and normalized to ⁇ - actin.
  • the EBs were fixed in 4% paraformaldehyde, cryo-preserved in 25% sucrose at 4°C overnight, snap frozen in OCT media (Leica), and sectioned to 6 ⁇ m using a cryotome (Leica CM3050S).
  • Sections were rinsed in PBS, fixed in 4% paraformaldehyde, permeabilized with 0.1 % triton X-100 in PBS, incubated in block buffer (PBS, 0.1% Triton X-100, 1 % BSA) and incubated overnight at 4°C in block buffer containing primary antibodies against Nkx2.5 (1 :200 dilution, Santa Cruz), ⁇ MHC (1 :100 dilution Santa Cruz), MLC2a (1 :500 dilution, Chemicon), MLC2v (1 :500 dilution, Chemicon), Tropomyosin (1 :50 dilution, Iowa Developmental Studies Hybridoma Bank), or alpha-actinin (1 :50 dilution, Chemicon).
  • block buffer PBS, 0.1% Triton X-100, 1 % BSA
  • EBs embryoid bodies
  • Differentiated EBs contain cells which express the cardiomyocyte transcription factor Nkx2.5 and cardiac structural proteins.
  • Nkx2.5 A highly specific and early marker of cardiac cell identity is the transcription factor Nkx2.5.
  • the Nkx2.5 marker is expressed ubiquitously in all mouse heart cell progenitors around the time the heart crescent is formed and is an important regulator of cardiac gene expression in the developing and adult animals in both mice and humans (McFadden et al, 2002).
  • the marker Nkx2.5 was detected by immunofluorescence in cells of EBs differentiated according to the above protocol. Structural markers of the cardiac contractile machinery expressed in fetal cardiomyocytes were co-expressed in ceils expressing Nkx2.5, confirming their cardiac identity ( Figure 1 ). It is known that ⁇ MHC and MLC2a are expressed throughout the myocardium in the developing mouse heart (Somi et al, 2006; Cai et al, 2005). Figure 1A and Figure 1 B show that ⁇ MHC and MLC2a were co-expressed by clusters of cells which expressed Nkx2.5.
  • Cardiomvocvtes co-express surface markers useful for antibody-based cell selection.
  • the surface marker CD166 (ALCAM) is an adhesive molecule expressed in the cardiac crescent and neural groove during mouse embryogenesis, and is lost in heart tissue by the time the mature heart has formed (Hirata et al, 2006). Therefore, cells isolated by expression of CD166 are likely to be developmentally immature and have the capacity to replicate in culture. In this study CD166 was co-expressed with Nkx2.5 by cells in the differentiated EBs 1 suggesting a fetal developmental stage of these cells ( Figure 2A).
  • the VEGF receptor Flk-1 is expressed by mouse cardiac progenitors and is shown to be expressed in mouse embryonic stem cells with potential to differentiate to beating cardiomyocytes (Moretti et al, 2006; Kattman et al, 2006).
  • Nkx2.5 expressing cells in the EBs of the present invention was shown to co- express Flk-1 ( Figure 2B). Further N-cadherin is expressed continuously during heart development, and is associated with cardiac progenitor cells isolated from differentiating mouse embryonic stem cells (Honda eif al, 2006). Accordingly Nkx2.5 expressing cells in the EBs also co-expressed the cell-cell adhesion molecule N-cadherin, ( Figure 2C).
  • a single cell suspension prepared from differentiated EBs by gentle digestion with Accumax reagent was shown to survive better than that when digested with trypsin, and better than undifferentiated human embryonic stem cells digested by either method as shown in Figure 3.
  • Approximately 40% of differentiated cells digested using Accumax were capable of adhering to a tissue culture dish and remaining viable for at least 48 hours ( Figure 3).
  • Subpopulations expressing the adhesion molecule CD166 were isolated from single cell suspensions by MACS as described in the materials and methods.
  • RNA extracted from cells immediately after sorting showed higher relative quantities of Nkx2.5 and ⁇ MHC transcripts in the CD166 expressing population than the CD166 negative or non-sorted populations ( Figure 4).
  • cells sorted based on expression of CD166 have fewer transcripts of the neural marker NeuroDI and the pluripotency marker Oct4. Therefore the sorted cardiomyocyte population of the current invention is depleted of non-cardiac cell types, including residual cells which presumably have the potential to form teratomas upon transplantation to a living animal.
  • CD166 Although only a small proportion of the starting differentiated cell population may express CD166, one of the key features of the cells isolated based on expression of CD166 is that the cells are capable of replication in culture.
  • the sorted cells selected by this method have the ability to grow rapidly in culture when plated at sub-confluent density.
  • CD166-selected cells plated at approximately 30% confluence ( Figure 5A) in tissue culture dishes coated with collagen I in medium containing 5-20% fetal calf serum were able to grow to 100% confluence in culture within 6 days (Figure 5B). Further during this growth phase it was seen 48 hours after plating that, approximately 25% of all adherent cells were in S-phase of the cell cycle as measured by BrdU incorporation (figure 5C).
  • fibronectin can be used to stimulate cardiomyocyte attachment to the tissue culture dish.
  • bovine serum can be circumvented by the addition of growth-stimulating factors in the medium such as fibroblast growth factor or vascular endothelial growth factor. It is important that the cells isolated by the method of the current invention retain their cardiac identity and have the potential to form functional, electrically coupled cardiomyocytes. It was seen that populations of cells selected by expression of CD166 grown to confluence, begin spontaneous contractions, implying the presence of electrically coupled, functional cardiomyocytes. When these cells were fixed and visualized for expression of the cardiac marker Nkx2.5 by immunofluorescence, large clusters of cells expressed Nkx2.5.
  • N-cadherin is a useful marker for the progenitor of cardiomyocytes differentiated from mouse ES cells in serum-free condition. Biochem Biophys Res Commun. 351(4):877-82.
  • Multipotent flk-1 + cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell.11(5):723-32.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

The present invention relates to new and/or improved methods of identification and selection of cardiomyocytes from human embryonic stem (hES) cells. The method further comprises isolating the selected cardiomyocyte population. There is also provided method for the screening for cardiovascular compounds comprising subjecting the said cardiomyocyte population to test compound/s, and observing and/or interpreting a response of the cardiomyocytes to the test compound.

Description

Method for identifying and selecting cardiomvocvtes
Field of the invention
The present invention relates to the identification and isolation of cardiomyocytes from human embryonic stem (hES) cells.
Background of the invention
Cardiovascular diseases remain the leading cause of mortality and morbidity world wide. Since adult cardiomyocytes do not regenerate, the death of these cells compromises the myocardial contractile function. For instance when the coronary vessel is occluded by a thrombus and the surrounding cardiomyocytes cannot be supplied with necessary energy sources from other coronary vessels. The loss of functional cardiomyocytes may lead to chronic heart failure. A potential route of restoring normal heart function is replacement of injured and dead cardiomyocytes by new functional cardiomyocytes.
The success of regenerative cardiac medicine depends on the availability of cardiomyocytes in sufficient numbers for the transplantation of the cardiac tissue. Cardiomyocytes have the potential to restore heart function after myocardial infarction or heart failure and human embryonic stem (hES) cells are potential source of transplantable cardiomyocytes (Siu et al, 2007).
A limitation in the study of cardiomyocytes has been the inability to identify these cells prospectively. The current protocols designed to direct the differentiation of human embryonic stem cells in vitro towards cells of the " cardiomyocyte lineage produce a heterogeneous population of cells of various identity and developmental stage. For the purpose of producing cell therapies or diagnostic cell products, pure or relatively pure cardiomyocyte populations are desired. Nearly pure populations of cardiomyocytes have been generated from mouse embryonic stem cells using a method requiring prior genetic transformation of the stem cells. Genetic transformation of stem cells is time consuming and may preclude the enriched cell population from use in the clinic. It would therefore be an advantage to have a method capable of isolating a population of differentiated cells enriched for cardiomyocytes from wild-type stem cells. Furthermore, it would be an advantage if a large proportion of the enriched cardiomyocytes were viable and capable of proliferation, allowing the enriched population to expand in culture for a number of population doublings.
Summary of the invention
The present invention addresses the problems above and in particular provides new and improved method of identification and isolation of cardiomyocytes from differentiated embryonic stem (ES) cells.
According to a first aspect, the present invention provides a method of identifying and selecting a cardiomyocyte population from a heterogeneous population of differentiated stem cells, comprising contacting the heterogeneous cell population with at least one agent that specifically binds to at least one cardiomyocyte marker and selecting the bound cells as cardiomyocytes.
The method further comprises isolating the selected cardiomyocyte population. There is also provided a method of propagating the selected cardiomyocyte population in culture. In particular, the at least one cardiomyocyte marker is selected from a group consisting of CD166 (ALCAM), VEGF receptor FIkI , N- cadherin, CD133 and CD117 (C-kit). More in particular the at least one cardiomyocyte marker is CD166 (ALCAM). The at least one cardiomyocyte marker may be a fetal marker. The identified cells may comprise at least 50% cardiomyocytes. In particular the identified cardiomyocytes may have a fetal phenotype. For example cardiomyocytes may be capable of proliferating in culture. In particular at least 25% of the identified cardiomyocytes may be in S phase of the cell cycle. More in particular the identified cardiomyocytes are capable of rhythmic contractions and/or forming electrically coupled cell clusters. As a non-limitative example, the stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoietic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells. In particular the stem cells may be human ES cells.
According to another aspect, the invention provides a cardiomyocyte population having the characteristics as herein defined. In particular, there is provided a cardiomyocyte population identified and /or isolated by the method according to the present invention. There is also provided a cardiomyocyte population isolated according to the method of the present invention.
According to yet another aspect, the invention provides a model for study of human cardiomyocytes in culture, comprising the cardiomyocyte population. The invention further provides a kit for cardiotoxic testing comprising the cardiomyocyte population.
Another aspect of the invention includes a method of preventing, repairing and/or treating at least one cardiac disorder in a subject, the said method comprising transplanting the isolated cardiomyocyte population. The cardiac disorder may be selected from a group consisting of myocardial infarction, cardiomyopathy, congestive heart failure, ventricular septal defect, atria septal defect, congenital heart defect and ventricular aneurysm.
According to a further aspect, the invention provides a model for testing suitability of cardiomyocytes for cardiac transplantation, said model comprising: A non-human animal having a measurable parameter of cardiac function wherein the said animal is capable of receiving an isolated cardiomyocyte population; and a means to determine cardiac function of the animal before and after transplantation of the isolated cardiomyocyte population. In particular the model may be an immunodeficient animal created as a model of cardiac muscle degeneration following infarct that is used as a universal acceptor of the isolated cardiomyocyte population. More in particular the animal model may be murine, ovine, bovine, porcine or a non-human primate. More in particular the parameter of cardiac function may be contractile function.
According to yet another aspect the invention provides a method of screening for cardiovascular compounds. In particular the method may comprise subjecting the said cardiomyocyte population to at least one test compound, and observing a cardiac specific response of the card io myocytes to at least one test compound. In particular the cardiac specific response may comprise alteration of Q-T wave.
Brief description of the figures
Figure 1 represents the expression of the cardiac transcription factor Nkx2.5 analysed by immunofluorescence following culturing of human embryonic stem cells for 14 days, under conditions which promote cardiomyocyte differentiation. The nuclei are counterstained with DAPI (blue), the area shown by arrows. Figure 1A represents the co-localization of Nkx2.5 (green) with the cardiac marker αMHC (red). The black and white view of Figure 1A represents the co- localization of Nkx2.5 (dark white) with the cardiac marker αMHC (light grey) Figure 1 B represents the co-localization of Nkx2.5 (red) with the cardiac marker MLC2a (green). The black and white view of Figure 1 B represents the co- localization of Nkx2.5 (light grey) with the cardiac marker MLC2a (dark white). Figure 1C represents the co-localization of Nkx2.5 (red) with the cardiac marker alpha-actinin (green). The black and white view of Figure 1C represents the co- localization of Nkx2.5 (light grey) with the cardiac marker alpha-actinin (dark white). Figure 1 D represents the co-localization of Nkx2.5 (red) with the cardiac marker tropomyosin (green). The black and white view of Figure 1 D represents the co- localization of Nkx2.5 (light grey) with the cardiac marker tropomyosin (dark white).
Figure 1E represents the co-localization of Nkx2.5 (red) with the cardiac marker MLC2v (green). The black and white view of Figure 1 E represents the co- localization of Nkx2.5 (light grey) with the cardiac marker MLC2v (dark white).
Figure 2 represents the expression of the cardiac transcription factor Nkx2.5 (green) analysed by immunofluorescence following culturing of human embryonic stem cells for 14 days under conditions which promote cardiomyocyte differentiation. The nuclei are counterstained with DAPI (blue), the area shown by arrows.
Figure 2A represents the co-localization of Nkx2.5 (green) with the cardiac marker CD166 (red). The black and white view of Figure 2A represents the co- localization of Nkx2.5 (dark white) with the cardiac marker CD166 (light grey). Figure 2B represents the co-localization of Nkx2.5 (green) with the cardiac marker Flk-1 (red). The black and white view of Figure 2B represents the co- localization of Nkx2.5 (dark white) with the cardiac marker Flk-1 (light grey). Figure 2C represents the co-localization of Nkx2.5 (green) with the cardiac marker N-cadherin (red). The black and white view of Figure 2C represents the co-localization of Nkx2.5 (dark white) with the cardiac marker N-cadherin (light grey).
Figure 3 represents percentage of surviving adherent cells at 48 hours, following digestion of the embryoid bodies and undifferentiated hES with trypsin or accumax reagent, and plating of the single cell suspensions on collagen I treated tissue culture dishes.
Figure 4 represents quantitative PCR analysis of RNA extracted from MACS sorted cells based on expression of CD166. Figure represents the expression of the cardiac markers Nkx2.5 and αMHC, neural marker NeuroDI , pluripotent cells marker Oct4 and endodermal cells marker AFP on cells isolated based on expression of CD166 enriched for cardiomyocytes.
Figure 5 represents proliferation of cells in collagen I coated culture dishes .isolated based on expression of CD166..
Figure 5A represents the sub-confluent layer of surviving cells attached to the dish after one day in culture. Figure 5B represents confluent layer of surviving cells attached to the dish after six days in culture.
Figure 5C represents the analysis of cells in S phase by BrdU (green) incorporation into the layer of surviving cells attached to the dish after two days in culture. In black and white view of Figure 5C represents the analysis of cells in S phase by BrdU (dark grey) incorporation into the layer of surviving cells attached to the dish after two days in culture
Figure 6 represents immunofluorescence analysis of the expression of Nkx2.5 (dark pink) and MLC2a (green) following the sorting of the 14 day old EBs based on expression of CD166, and plated on collagen I coated dishes in medium containing bovine serum and allowed to grow to confluence over a period of five days. Nuclei are counterstained with DAPI (blue). In the black and white view the Nk2.5 stained cells appear to be dark white while the DAPI counterstain appear as light grey. Figure 6A represents CD166+ cells expressing the cardiomyocyte marker Nkx2.5 (dark pink). The black and white view of Figure 6A represents CD166+ cells expressing the cardiomyocyte marker Nkx2.5 (dark white). Figure 6B represents that CD166- cells do not express or express very little of the cardiomyocyte marker Nkx2.5 (dark pink). The black and white view Figure 6B represents that CD166- cells do not express or express very little of the cardiomyocyte marker Nkx2.5 (dark white)
Figure 6C represents CD166+ cells expressing the cardiomyocyte markers Nkx2.5 (dark pink) and MLC2a (green). The black and white view Figure 6C represents CD166+ cells expressing the cardiomyocyte markers Nkx2.5 (dark white) and MLC2a (grey).
Brief description of the sequences
SEQ ID NO. 1 refers to Actin forward primer 5'- CAATGTGGCCGAGGACTTTG -3'
SEQ ID NO. 2 refers to Actin reverse primer
5'- CATTCTCCTTAGAGAGAAGTG -3' SEQ ID NO. 3 refers to Nkx2.5 forward primer
5'- AGAAGACAGAGGCGGACAAC -3' SEQ ID NO. 4 refers to Nkx2.5 reverse primer
5'- CGCCGCTCCAGTTCACAG -3' SEQ ID NO. 5 refers to αMHC forward primer
5'- ATTGCTGAAACCGAGAATGG -3' SEQ ID NO. 6 refers to αMHC reverse primer 5'- CGCTCCTTGAGGTTGAAAAG -3'
SEQ ID NO. 7 refers to NeuroD forward primer
5'- GCCCCAGGGTTATGAGACTA -3' SEQ ID NO. 8 refers to NeuroD reverse primer
5'- GTCCAGCTTGGAGGACCTT -3' SEQ ID NO. 9 refers to Oct4 forward primer
5'- GGCAACCTGGAGAATTTGTT -3' SEQ ID NO. 10 refers to Oct4 reverse primer
5'- GCCGGTTACAGAACCACACT -3' SEQ ID NO. 11 refers to AFP forward primer
5'- GTAGCGCTGCAAACAATGAA -3' SEQ ID NO. 12 refers to AFP reverse primer
5'- TCCAACAGGCCTGAGAAATC -3'
Detailed description of the invention
Bibliographic references mentioned in the present specification are for convenience listed in the form of a list of references and added at the end of the examples. The whole content of such bibliographic references is herein incorporated by reference.
The present invention provides new and/or improved method of identification and isolation of cardiomyocytes from differentiated embryonic stem (ES) cells.
According to one aspect, the invention provides a method of identifying and selecting a cardiomyocyte population from a heterogeneous population of differentiated stem cells, comprising contacting the heterogeneous cell population with at least one agent that specifically binds to at least one cardiomyocyte marker and selecting cells bound to the said agent as cardiomyocytes. The heterogeneous population of differentiated stem cells may be prepared according to the method described in WO 2007/030870 (the content of which is herein incorporated by reference).
The method further comprises isolating the selected cardiomyocyte population.
There is also provided a method of propagating the selected cardiomyocyte population in culture. In particular, the at least one cardiomyocyte marker is selected from the group consisting of CD166 (ALCAM), VEGF receptor FIkI , N- cadherin, CD133 and CD117 (C-kit). More in particular the at least one cardiomyocyte marker is CD166 (ALCAM). The at least one cardiomyocyte marker may be a fetal marker.
Sorting of cells based on surface marker expression may be accomplished by using any technology known in the art. For example, sorting of cells based on surface marker expression may be accomplished by using Flow Assisted Cell Sorting (FACS) or Automated Magnetic Cell Sorting (MACS) technology. The preparation of the cells for FACS is similar to preparation of cells for MACS except that the secondary antibody is conjugated to a FACS-compatible fluorophore instead of a magnetic microbead.
At least 50% of the identified, selected and/or isolated cells according to the invention may comprise cardiomyocytes. In particular, 55%, 60%, 70%, 80% or 90% of the isolated cells may comprise cardiomyocytes. In particular the identified, selected and/or isolated cardiomyocytes may have a fetal phenotype.
The cardiomyocytes may be capable of proliferating in culture. In particular at least 25% of the identified cardiomyocytes may be in S phase of the cell cycle. More in particular, the identified cardiomyocytes are capable of rhythmic contractions and/or forming electrically coupled cell clusters.
As a non-limiting example, the stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoitic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells. In particular the stem cells may be human ES cells. In particular the stem cells may be isolated ES cells. For example, the ES cell may be obtained from at least one ES cell line recognised the NIH human stem cell registry (http://stemcells.nih.gov/research/registry/defaultpage.asp) according to the methods and ethical standards mentioned therein. More in particular, the hES cell line hES3 from ES Cell International may be used.
"Stem cells" as described herein refers to a stem cell that is undifferentiated prior to culturing and is capable of undergoing differentiation. The stem cells may be selected from a group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoietic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells. In particular the stem cell may be human embryonic stem (hES) cells. For example the stem cell may be derived from a cell culture, such as hES cells. The stem call may be derived from an embryonic cell line or embryonic tissue. The embryonic stem cells may be cells which have been cultured and maintained in an undifferentiated state.
The stem cells suitable for use in the present methods may be derived from a patient's own tissue. This would enhance compatibility of differentiated tissue grafts derived from stem cells with the patient.
Differentiated stem cells may express markers on their cell surface that may be indicative of a specific cell type, for example indicative of cardiomyocytes. The markers may be used to identify and isolate the differentiated cardiomyocytes from other differentiated cells and undifferentiated stem cells. "Markers", as used herein, are polypeptide molecules that are expressed on a cell of interest.
The specific marker may be present only in the cells of interest, or encompass the cells of interest, or detectable level of the marker is sufficiently higher in the cells of interest, compared to other cells, such that the cells of interest can be identified, using any of a variety of methods as known in the art. It will be understood by those of skill in the art that expression is a relative term, and the expression will vary from other cell types. For example, a progenitor cell may express a polypeptide that is not found in the fully differentiated progeny cell. A cell of interest may express a polypeptide that is not expressed in surrounding tissues, e.g. the cardiomyocyte cells of fetal phenotype may express CD166 polypeptides not found in mature cardiomyocytes or on other cells of a non- cardiomyocyte lineage. This specificity is sufficient for purposes of cell identification and isolation. Therefore, "fetal markers" as used herein refer to a marker on a cell, in particular cardiomyocytes that is indicative of the fetal phenotype of the cells. Fetal phenotype further refers to cells that are capable of proliferating in culture. Some fetal markers of interest in the present invention include CD166 (ALCAM), VEGF receptor FIkI 1 N-cadherin, CD133, CD117 (C- kit), Nkx2.5, α-MHC, MLC2a, MLC2v, α-actinin and tropomyosin. In particular, fetal markers of interest in the present invention include CD166 (ALCAM), VEGF receptor Flk1 , N-cadherin, CD133, CD117 (C-kit). More in particular the cardiomyocyte marker may be CD166 (ALCAM). These markers are well known in the art, and agents (reagents) for the detection thereof are widely available. In a typical assay for detection and/or isolation, a heterogeneous population of differentiated stem cell is contacted with at least one a marker-specific "agent", and detecting directly or indirectly the presence of the complex formed. The term "agent" as used herein refers to a molecule capable of binding to another molecule, for example the marker on the cell surface, through chemical or physical means, wherein the agent and the marker form a binding pair. For example antibodies specific for these cell surface markers are commercially available, or may be produced using conventional methods as known in the art, therefore the antibodies and markers form a binding pair. Of particular interest is the use of antibodies as affinity reagents. Conveniently, these antibodies are conjugated with a label for use in separation. Labels include magnetic beads, which allow for direct separation on magnetic assisted cell sorter (MACS), biotin, which can be removed with avidin or streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter (FACS), or the like, to allow for ease of separation of the particular cell type. Fluorochromes that find use include phycobiliproteins, e.g. phycoerythrin and allophycocyanins, fluorescein and Texas red. Frequently each antibody is labeled with a different fluorochrome, to permit independent analysis or sorting for each marker. Monoclonal antibodies specific for the markers may be produced in accordance with conventional ways, immunization of a mammalian host, e.g. mouse, rat, guinea pig, cat, dog, etc., fusion of resulting splenocytes with a fusion partner for immortalization and screening for antibodies having the desired affinity to provide monoclonal antibodies having a particular specificity. These antibodies can be used for affinity chromatography, ELISA, RIA, and the like. The antibodies may be labelled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other label which will allow for detection of complex formation between the labelled antibody and its complementary epitope.
In particular the invention provides methods of preventing, repairing and/or treating at least one cardiac disorder in a subject, the method comprising transplanting the cardiomyocyte population in a subject. The subject is, in particular, a subject in need of the treatment thereof. The disorder as, used herein, include but are not limited to myocardial infarction, cardiomyopathy, congestive heart failure, ventricular septal defect, atria septal defect, congenital heart defect and ventricular aneurysm. In this aspect of the invention, the method includes introducing a cardiomyocyte population of the invention into cardiac tissue of a subject. In particular the isolated cardiomyocyte population is transplanted into damaged cardiac tissue of the subject. More in particular the method results in the restoration of cardiac function in a subject. The cardiomyocyte population may resemble a human fetal atrial cell in culture. In particular the cardiomyocyte population may resemble a human fetal pacemaker cell in culture. More in particular the cardiomyocyte population may comprise plurality of isolated cardiomyocytes wherein the cardiomyocytes may be coupled. The coupling may be, for example, through gap junctions and/or adherens junctions, wherein the coupling is electrical. The subject may be a human or non-human animal.
The present invention also provides at least one cardiomyocyte population identified, selected and/or isolated according to the method of the present invention for use in medicine. In particular, in preventing, repairing and/or treating at least one cardiac disorder in a subject. There is also provided the use of at least one cardiomyocyte population identified, selected and/or isolated according to the method of the present invention for the preparation of a medicament in preventing, repairing and/or treating at least one cardiac disorder in a subject.
The present invention also provides a cardiac model for testing the ability of the isolated cardiomyocyte population to restore cardiomyocyte function. In order to test the effectiveness of transplanted cardiomyocyte population in vivo, it is important to have a reproducible animal model with a measurable parameter of cardiac function. The parameters used should clearly distinguish control and experimental animals so that the effects of the transplantation can be adequately determined. A host animal, such as, but not limited to, an immunodeficient mouse may be used as a 'universal acceptor' of cardiomyocytes produced by the methods of the present invention.
The myocardial model of the present invention is designed to assess the extent of cardiac repair following transplant of cardiomyocytes into the host animal. In particular, the host animal may be an immunodeficient animal created as a model of cardiac muscle degeneration following infarct that is used as a universal acceptor of isolated cardiomyocytes. The non-human animal may be any species including but not limited to murine, ovine, canine, bovine, porcine and any non-human primates. Parameters used to measure cardiac repair in these animals may include, but are not limited to, electrophysiological characteristic of heart tissue or various heart functions. For instance, contractile function may be assessed in terms of volume and pressure changes in a heart. Methods of assessing heart function and cardiac tissue characteristics may also involve techniques known to person skilled in the art.
The invention further provides cardiomyocytes produced using the methods of the current invention that may be used for transplantation, cell therapy or gene therapy. In particular the invention provides the use of cardiomyocytes produced using the methods of the current invention, in a cardiac model for testing the ability to restore cardiac function. More in particular the invention provides the use of cardiomyocytes in a cardiac model designed to assess the extent of cardiac repair following transplant of cardiomyocytes into a suitable host animal.
The present invention also provides a model for study of human cardiomyocytes in culture, comprising the cardiomyocytes isolated by the method of the current invention. This model may be used in the development of cardiomyocyte transplantation therapies.
According to yet another aspect the invention provides a method of screening for cardiovascular compounds. In particular the method may comprise subjecting the said cardiomyocyte population to at least one test compound, and observing a cardiac specific response of the cardiomyocytes to at least one test compound. In particular, the specific cardiac response may be monitored by the changes of beat frequency, amplitude and/or duration of the cardiomyocyte(s) to at least one test compound. More in particular the cardiac specific response may comprise alteration of Q-T wave.
There is also provided a kit for cardiotoxic testing or for screening of cardiovascular compound(s) comprising at least one cardiomyocyte population according to the invention. There is also provided a kit for preventing, repairing and/or treating at least one cardiac disorder in a subject, the kit comprising at least one cardiomyocyte population according to the invention. The kit may further comprise instructions for use.
Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention.
EXAMPLES
Materials and Methods hES cell culture
The hES cell line hES3 from ES Cell International
(http://stemcells.nih.gov/research/registry/esci.asp) were maintained on human fibroblasts in KO-DMEM with 20% KOSR in 0.1 mM beta-mercaptoethoethanal, 1 % MEM non-essential amino acids, 2mM L-glutamine, bFGF (10ng/ml) with or without antibiotics (Penicillin/Streptomycin; all reagents from Invitrogen). The hES cells were passaged by treatment with collagenase I (however, collagenase IV may also be used) (Gibco) for 3 minutes followed by mechanical dissociation. Harvested cells were transferred to newly prepared feeder cells.
hES differentiation
The pluripotent hES grown on human feeders in 10cm dishes were rinsed with phosphate buffered saline (PBS). PBS was then replaced by fresh stem cell maintenance medium. The dish was scored using a pipette tip such that each colony was divided approximately in two cell clusters. Cell clusters were scraped from the substrate and transferred to a conical tube. The cell clusters were allowed to settle to the bottom of the conical tube and the media was aspirated. The media was replaced by fresh stem cell maintenance medium. The cell clusters were transferred to plastic dishes to discourage cell attachment (Ultra-low attach dishes, Costar). The dishes were incubated in the tissue culture incubators for a period of 24 hours. After the 24 hour culture, embryoid bodies (EBs) were formed from the pluripotent cell clusters in suspension. The dishes were tilted such that the embryoid bodies sank to the bottom and the media was aspirated. The medium was replaced by defined basic serum free (bSFS) medium comprising DMEM supplemented with 1x MEM non-essential amino acids (Invitrogen), 2mM L-Glutamine (Invitrogen), 0.0055 mg/ml Transferrin (Roche), 5 ng/ml sodium Selenite (Sigma), 0.1 mM beta-mercaptoethanol, with or without Penicillin/Streptomycin (Invitrogen). which promotes cardiomyocyte differentiation as described in WO 2007/030870.
To further encourage differentiation towards the cardiomyocyte lineage, 5μg/ml of the compound SB203580, as described in WO 2007/030870, was added. The embryoid bodies were cultured in these conditions for an additional 12 days. During this period, the culture medium was changed every 3-4 days.
Digestion of emhryoid bodies to a single cell suspension.
The EBs were transferred to a conical tube and allowed to settle. The medium was aspirated and the EBs rinsed with PBS not containing either magnesium or calcium. EBs were incubated at 37°C in either undiluted Accumax reagent (Innovative Cell Technologies), or a 0.25 or 0.005% solution of trypsin (Roche) in phosphate buffered saline. The enzymatic reactions were arrested by the addition of differentiation medium containing 20% fetal calf serum. Residual clusters of cells were removed by passing the cell suspension through a filter with maximum pore size of 40μm.
Magnet assisted cells sorting (MACS)
The single cell suspensions were pelleted in a centrifuge refrigerated to 40C at approximately 300 gravities for 15 minutes. The cell pellet was resuspended in an immunoglobulin blocking buffer (FcR blocking buffer, Miltenyi Biotec) at a concentration of 1X106 cells per 100μl. A concentration of 0.5 to 5μg/ml of antibody (mouse monoclonal ab23829, Abeam) which binds the cell surface antigen CD166 was added to the cell suspension. The cell suspension was incubated for 30 minutes at 40C while rocking. The cells were pelleted again in a refrigerated centrifuge at approximately 300 gravities for 10 minutes. The blocking buffer containing the anti-CD166 antibody was aspirated and replaced by 8OuI per 1X106 cells supplemented with 20ul of magnetic microbead conjugated antibody which recognizes the anti-CD166 antibody (rat anti-mouse igG2a+b microbeads, 472-01 Miltenyi Biotec) and was incubated for 30 minutes at 4°C while rocking. The cells were pelleted and resuspended in fresh blocking buffer. Cells bound to magnetic microbeads were separated from the unbound cell population by being passed through a column held in a strong magnetic field (Miltenyi Biotec columns, Miltenyi Biotec magnetic holder). The sorted cells were pelleted, resuspended in bSFS media containing 5μM SB203580 and 20% fetal calf serum and plated in tissue culture dishes pre-coated with 100μg/ml of collagen I (Roche). The media was changed every 2-3 days. After the cultures had grown to confluence, the medium was replaced by bSFS medium containing 5μM SB203580 but without fetal calf serum.
Quantitative PCR
Total RNA was isolated using the RNeasy kit (Qiagen), treated with on-filter DNase and quantified by UV absorption. One μg of RNA was converted to cDNA using M-MuLV reverse transcriptase (New England Biolabs) using random hexamer primers and following manufacturer's instructions. Quantitative PCR was performed with 50 ng of each reverse transcriptase reaction, 250 nM of forward and reverse primer, IxSYBR green PCR master mix (Bio-RAD) and analyzed by iCycler thermocycler (Bio-RAD). Primers comprising the sequence of SEQ ID NO:1 and SEQ ID NO:2 were used to detect binding amplification of the actin sequence, primers comprising the sequence of SEQ ID NO: 3 and SEQ ID NO:4 were used to detect Nkx2.5, primers comprising the sequence of SEQ ID NO:5 and SEQ ID NO:6 were used to detect αMHC sequence, primers comprising the sequence of SEQ ID NO: 7 and SEQ ID NO: 8 were used to NeuroD, primers comprising the sequence of SEQ ID NO. 9 and SEQ ID NO: 10 were used to amplify oct4 sequence and primers comprising the sequence of SEQ ID NO. 11 and SEQ ID NO: 12 were used to amplify AFP sequence. Expression was calculated based on a standard curve and normalized to β- actin.
Immunofluorescence The EBs were fixed in 4% paraformaldehyde, cryo-preserved in 25% sucrose at 4°C overnight, snap frozen in OCT media (Leica), and sectioned to 6 μm using a cryotome (Leica CM3050S). Sections were rinsed in PBS, fixed in 4% paraformaldehyde, permeabilized with 0.1 % triton X-100 in PBS, incubated in block buffer (PBS, 0.1% Triton X-100, 1 % BSA) and incubated overnight at 4°C in block buffer containing primary antibodies against Nkx2.5 (1 :200 dilution, Santa Cruz), αMHC (1 :100 dilution Santa Cruz), MLC2a (1 :500 dilution, Chemicon), MLC2v (1 :500 dilution, Chemicon), Tropomyosin (1 :50 dilution, Iowa Developmental Studies Hybridoma Bank), or alpha-actinin (1 :50 dilution, Chemicon). After three rinses in PBS, slides were incubated for one hour at room temperature in blocking buffer containing secondary antibodies (1 :1000 dilution, Chemicon, Zymed), incubated for one hour at room temperature, rinsed three times in PBS, incubated in DAPI (1 :2000 dilution) for 10 minutes, rinsed, and mounted with Fluorosave (Calbiochem).
BrdU incorporation
Determination of cell proliferation was performed using in situ Cell Proliferation Kit, FLUOS (Roche) and following manufacturer's instructions. Briefly, 10 μM BrdU was added to the cell medium for a period of one or three hours. Cells were then fixed for immunohistochemistry and DNA was denatured by 20 min incubation in 4M HCI. Results
Differentiation to cardiomyocyte lineage
Stem cells were stimulated to differentiate towards the cardiomyocyte lineage following the methods described in WO 2007/030870. At the end of this culture period, lasting two weeks, clusters of cells in suspension, termed embryoid bodies (EBs) were produced. A large proportion of the EBs began spontaneous rhythmic contractions and contained cells which expressed markers of the cardiomyocyte lineage.
Differentiated EBs contain cells which express the cardiomyocyte transcription factor Nkx2.5 and cardiac structural proteins.
A highly specific and early marker of cardiac cell identity is the transcription factor Nkx2.5. The Nkx2.5 marker is expressed ubiquitously in all mouse heart cell progenitors around the time the heart crescent is formed and is an important regulator of cardiac gene expression in the developing and adult animals in both mice and humans (McFadden et al, 2002).
The marker Nkx2.5 was detected by immunofluorescence in cells of EBs differentiated according to the above protocol. Structural markers of the cardiac contractile machinery expressed in fetal cardiomyocytes were co-expressed in ceils expressing Nkx2.5, confirming their cardiac identity (Figure 1 ). It is known that αMHC and MLC2a are expressed throughout the myocardium in the developing mouse heart (Somi et al, 2006; Cai et al, 2005). Figure 1A and Figure 1 B show that αMHC and MLC2a were co-expressed by clusters of cells which expressed Nkx2.5. Further since alpha actinin and tropomyosin are expressed in all cardiac contractile tissue, the co-expression of these markers by cells which expressed Nkx2.5 was seen as shown in Figure 1 C and Figure 1 D. It is further known that MLC2v expression is restricted to ventricle and atrioventricular canal when specification of these structures occurs (Cai et al, 2005). Accordingly MLC2v was not detected in differentiated EBs, suggesting that these cells are homologous to a fetal developmental stage wherein ventricular specification had not yet occurred (Figure 1 E).
Cardiomvocvtes co-express surface markers useful for antibody-based cell selection.
The surface marker CD166 (ALCAM) is an adhesive molecule expressed in the cardiac crescent and neural groove during mouse embryogenesis, and is lost in heart tissue by the time the mature heart has formed (Hirata et al, 2006). Therefore, cells isolated by expression of CD166 are likely to be developmentally immature and have the capacity to replicate in culture. In this study CD166 was co-expressed with Nkx2.5 by cells in the differentiated EBs1 suggesting a fetal developmental stage of these cells (Figure 2A). The VEGF receptor Flk-1 is expressed by mouse cardiac progenitors and is shown to be expressed in mouse embryonic stem cells with potential to differentiate to beating cardiomyocytes (Moretti et al, 2006; Kattman et al, 2006). Accordingly Nkx2.5 expressing cells in the EBs of the present invention was shown to co- express Flk-1 (Figure 2B). Further N-cadherin is expressed continuously during heart development, and is associated with cardiac progenitor cells isolated from differentiating mouse embryonic stem cells (Honda eif al, 2006). Accordingly Nkx2.5 expressing cells in the EBs also co-expressed the cell-cell adhesion molecule N-cadherin, (Figure 2C).
Isolation of cell population enriched for cardiomvocvtes
A single cell suspension prepared from differentiated EBs by gentle digestion with Accumax reagent was shown to survive better than that when digested with trypsin, and better than undifferentiated human embryonic stem cells digested by either method as shown in Figure 3. Approximately 40% of differentiated cells digested using Accumax were capable of adhering to a tissue culture dish and remaining viable for at least 48 hours (Figure 3). Subpopulations expressing the adhesion molecule CD166 were isolated from single cell suspensions by MACS as described in the materials and methods.
RNA extracted from cells immediately after sorting showed higher relative quantities of Nkx2.5 and αMHC transcripts in the CD166 expressing population than the CD166 negative or non-sorted populations (Figure 4). In addition, cells sorted based on expression of CD166 have fewer transcripts of the neural marker NeuroDI and the pluripotency marker Oct4. Therefore the sorted cardiomyocyte population of the current invention is depleted of non-cardiac cell types, including residual cells which presumably have the potential to form teratomas upon transplantation to a living animal.
Although only a small proportion of the starting differentiated cell population may express CD166, one of the key features of the cells isolated based on expression of CD166 is that the cells are capable of replication in culture. The sorted cells selected by this method have the ability to grow rapidly in culture when plated at sub-confluent density. CD166-selected cells plated at approximately 30% confluence (Figure 5A) in tissue culture dishes coated with collagen I in medium containing 5-20% fetal calf serum were able to grow to 100% confluence in culture within 6 days (Figure 5B). Further during this growth phase it was seen 48 hours after plating that, approximately 25% of all adherent cells were in S-phase of the cell cycle as measured by BrdU incorporation (figure 5C). Alternatively, other adhesive substrates such as fibronectin can be used to stimulate cardiomyocyte attachment to the tissue culture dish. In addition, the use of bovine serum can be circumvented by the addition of growth-stimulating factors in the medium such as fibroblast growth factor or vascular endothelial growth factor. It is important that the cells isolated by the method of the current invention retain their cardiac identity and have the potential to form functional, electrically coupled cardiomyocytes. It was seen that populations of cells selected by expression of CD166 grown to confluence, begin spontaneous contractions, implying the presence of electrically coupled, functional cardiomyocytes. When these cells were fixed and visualized for expression of the cardiac marker Nkx2.5 by immunofluorescence, large clusters of cells expressed Nkx2.5. Visual count of representative fields of Nkx2.5 expressing cells revealed that cardiomyocytes represented greater than 50% of the total cell population (Figure 6A). However cells that were negative for CD166 marker showed only basal level expression of Nkx2.5 (Figure 6B). Cells expressing Nkx2.5 also co- expressed the cardiac structural marker myosin light chain 2a (MLC2a) confirming their cardiac identity as shown in Figure 6C.
All the above experiments were performed with stringent controls. The results from the experiments suggest that identification and isolation of cardiomyocytes based on the expression of CD166 marker is an efficient way of obtaining a population of cells enriched in cardiomyocytes. Further, in addition to the surface marker CD166, selection of cells can be based on expression of other markers including FIkI , N-cadherin, CD133, and CD117. Further in addition to MACS, sorting of cells based on surface marker expression can be accomplished equally as well using other methods known to those skilled in the art, for example, FACS.
Finally, the invention as described herein is susceptible to variations, modifications and/or additions other than those specifically described and it is understood that the invention includes all such variations, modifications and/or additions which fall within the scope of the description as described herein. References:
Cai CL, Zhou W, Yang L, Bu L, Qyang Y, Zhang X, Li X, Rosenfeld MG, Chen J, Evans S., 2005. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development.132(10):2475-87.
Hirata H, Murakami Y, Miyamoto Y, Tosaka M, lnoue K, Nagahashi A, Jakt LM, Asahara T, Iwata H, Sawa Y, Kawamata S., 2006 ALCAM (CD166) is a surface marker for early murine cardiomyocytes. Cells Tissues Organs.184(3-4): 172-80.
Honda M, Kurisaki A, Ohnuma K, Okochi H, Hamazaki TS, Asashima M., 2006. N-cadherin is a useful marker for the progenitor of cardiomyocytes differentiated from mouse ES cells in serum-free condition. Biochem Biophys Res Commun. 351(4):877-82.
Kattman SJ, Huber TL, Keller GM., 2006. Multipotent flk-1 + cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell.11(5):723-32.
McFadden DG, Olson EN., 2002. Heart development: learning from mistakes. Curr Opin Genet Dev. 12(3):328-35. Review.
Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qyang Y, Bu L, Sasaki M, Martin-Puig S, Sun Y, Evans SM, Laugwitz KL, Chien KR.,2006. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell.127(6): 1151-65
Siu CW, Moore JC, Li RA., 2007. Human embryonic stem cell-derived cardiomyocytes for heart therapies. Cardiovasc Hematol Disord Drug Targets. 7(2):145-52.
Somi S, Klein AT, Houweling AC, Ruijter JM, Buffing AA, Moorman AF, van den Hoff MJ., 2006. Atrial and ventricular myosin heavy-chain expression in the developing chicken heart: strengths and limitations of non-radioactive in situ hybridization. J Histochem Cytochem. 54(6):649-64.
WO 2007/030870.

Claims

Claims
1. A method of identifying and selecting a cardiomyocyte population from a heterogeneous population of differentiated stem cells, comprising contacting the heterogeneous cell population with at least one agent that specifically binds to at least one cardiomyocyte marker and selecting cells bound to the said agent as cardiomyocytes.
2. The method according to claim 1 , further comprising a step of isolating the selected cardiomyocyte population.
3. The method according to claim 2, further comprising a step of propagating the selected cardiomyocyte population in culture.
4. The method according to claim 1 , wherein the cardiomyocyte marker is selected from a group consisting of CD166 (ALCAM), VEGF receptor FIkI , N- cadherin, CD133 and CD117 (C-kit).
5. The method according to claim 1 , wherein the cardiomyocyte marker is CD166 (ALCAM).
6. The method according to claim 1 , wherein the cardiomyocyte marker is a fetal marker.
7. The method according to claim 2, wherein at least 50% of the isolated cells comprise cardiomyocytes.
8. The method according to claim 1 , wherein the identified cardiomyocytes have a fetal phenotype.
9. The method according to claim 1 , wherein the identified cardiomyocytes are capable of proliferating in culture.
10. The method according to claim 1 , wherein the identified cardiomyocytes are capable of rhythmic contractions and/or forming electrically coupled cell clusters.
11. The method according to claim 1 , wherein the stem cells are selected from the group consisting of embryonic stem (ES) cell, pluripotent stem cells, hematopoietic stem cells, totipotent stem cells, mesenchymal stem cells, neural stem cells and adult stem cells.
12. The method according to claim 11 , wherein the stem cells are human ES cells.
13. A cardiomyocyte population, identified by the method according to claim 1.
14. A cardiomyocyte population, isolated by the method according to claim 2.
15. A model for study of human cardiomyocytes in culture, comprising the cardiomyocytes according to claim 14.
16. A kit for cardiotoxic testing comprising the cardiomyocyte(s) according to claim 14.
17. A method of preventing, repairing and/or treating at least one cardiac disorder in a subject, the said method comprising transplanting the cardiomyocyte population isolated and/or enriched according to claim 14.
18. A model for testing suitability of cardiomyocytes for cardiac transplantation, said model comprising:
A non-human animal having a measurable parameter of cardiac function wherein the said animal is capable of receiving an isolated cardiomyocyte population according to claim 14 by transplantation; and a means to determine cardiac function of the animal before and after transplantation of the isolated cardiomyocyte population.
19. A method of screening for cardiovascular compounds, the said method comprising subjecting a cardiomyocyte population according to claim 14 to test at least one compound, and observing and/or interpreting a cardiac specific response of the cardiomyocytes to the at least one test compound.
20. The method according to claim 19, wherein the cardiac specific response comprises alteration of the Q-T wave.
PCT/SG2007/000226 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes WO2009017460A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/SG2007/000226 WO2009017460A1 (en) 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes
US12/671,274 US20100247493A1 (en) 2007-07-31 2007-07-31 Method for Identifying and Selecting Cardiomyocytes
AU2007357127A AU2007357127B2 (en) 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes
GB1002084.0A GB2465502B (en) 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes
IL203575A IL203575A (en) 2007-07-31 2010-01-28 Method for identifying and selecting cardiomyocytes
US14/958,923 US20160320409A1 (en) 2007-07-31 2015-12-03 Method for identifying and selecting cardiomyocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2007/000226 WO2009017460A1 (en) 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/671,274 A-371-Of-International US20100247493A1 (en) 2007-07-31 2007-07-31 Method for Identifying and Selecting Cardiomyocytes
US14/958,923 Continuation US20160320409A1 (en) 2007-07-31 2015-12-03 Method for identifying and selecting cardiomyocytes

Publications (2)

Publication Number Publication Date
WO2009017460A1 true WO2009017460A1 (en) 2009-02-05
WO2009017460A8 WO2009017460A8 (en) 2009-07-23

Family

ID=40304567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2007/000226 WO2009017460A1 (en) 2007-07-31 2007-07-31 Method for identifying and selecting cardiomyocytes

Country Status (5)

Country Link
US (2) US20100247493A1 (en)
AU (1) AU2007357127B2 (en)
GB (1) GB2465502B (en)
IL (1) IL203575A (en)
WO (1) WO2009017460A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2609194A1 (en) * 2010-08-27 2013-07-03 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
EP2691512A1 (en) * 2011-03-29 2014-02-05 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
US9395354B2 (en) 2011-07-21 2016-07-19 The Board Of Trustees Of The Leland Stanford Junior University Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof
WO2017172086A1 (en) * 2016-02-19 2017-10-05 Leung Chuen Yan Genetic markers for engraftment of human cardiac ventricular progenitor cells
AU2017239493B2 (en) * 2010-08-27 2019-10-31 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on SIRPA expression
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
US10597637B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US11186820B2 (en) 2017-08-23 2021-11-30 Procella Therapeutics Ab Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875858C (en) 2011-06-21 2022-05-03 Georgia Tech Research Corporation Adhesive signature-based methods for the isolation of stem cells and cells derived therefrom
ES2615396T3 (en) 2013-08-22 2017-06-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Method to produce cardiac muscle by engineering (EHM)
CA3017125A1 (en) * 2016-03-09 2017-09-14 Aal Scientifics, Inc. Neural stem cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029084A2 (en) * 2004-09-03 2006-03-16 Cornell Research Foundation, Inc. Bone marrow derived oct3/4+ stem cells
WO2007030870A1 (en) * 2005-09-12 2007-03-22 Es Cell International Pte Ltd Cardiomyocyte production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006078034A1 (en) * 2005-01-24 2008-06-19 財団法人ヒューマンサイエンス振興財団 Cells capable of differentiating into cardiomyocytes
AU2006326853B2 (en) * 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029084A2 (en) * 2004-09-03 2006-03-16 Cornell Research Foundation, Inc. Bone marrow derived oct3/4+ stem cells
WO2007030870A1 (en) * 2005-09-12 2007-03-22 Es Cell International Pte Ltd Cardiomyocyte production

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BABA ET AL.: "Flk1+ cardiac stem/progenitor cells derived from embryonic stem cells improve cardiac function in a dilated cardiomyopathy mouse model", CARDIOVASCULAR RESEARCH, vol. 76, no. 1, October 2007 (2007-10-01), pages 119 - 131, XP002561542, DOI: doi:10.1016/j.cardiores.2007.05.013 *
BAYES-GERNIS ET AL.: "Identification of cardiomyogenic lineage markers in untreated human bone marrow-derived mesenchymal stem cells", TRANSPLANTATION PROCEEDINGS, vol. 37, no. 9, November 2005 (2005-11-01), pages 4077 - 4079, XP005229146, DOI: doi:10.1016/j.transproceed.2005.09.103 *
BELLAFIORE ET AL.: "Research of cardiomyocyte precursors in adult rat heart", TISSUE AND CELL, vol. 38, no. 6, December 2006 (2006-12-01), pages 345 - 351, XP005739808, DOI: doi:10.1016/j.tice.2006.08.003 *
HIRATA ET AL.: "ALCAM (CD166) is a surface marker for early murine cardiomycocytes", CELLS TISSUES ORGANS, vol. 184, no. 3-4, 2006, pages 172 - 180 *
HONDA ET AL.: "N-cadherin is a useful marker for the progenitor of cardiomycytes differentiated from mouse ES cells in serum-free condition", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 351, no. 4, December 2006 (2006-12-01), pages 877 - 882 *
LAGOSTENA ET AL.: "Electrophysiological properties of mouse bone marrow c-kit+ cells co-cultured onto neonatal cardiac myocytes", CARDIOVASCULAR RESEARCH, vol. 66, no. 3, June 2005 (2005-06-01), pages 482 - 492, XP004944020, DOI: doi:10.1016/j.cardiores.2005.01.018 *
STEEL ET AL.: "Stem-like cells traffic from heart ex vivo, expand in vitro, and can be transplanted in vivo", THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. 24, no. 11, November 2005 (2005-11-01), pages 1930 - 1939 *
WANG ET AL.: "Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord", STEM CELLS, vol. 22, 2004, pages 1330 - 1337 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994821B2 (en) 2010-08-27 2018-06-12 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on SIRPA expression
EP2609194A1 (en) * 2010-08-27 2013-07-03 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
EP2609194A4 (en) * 2010-08-27 2014-02-19 Univ Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
AU2017239493B2 (en) * 2010-08-27 2019-10-31 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on SIRPA expression
EP2691512A4 (en) * 2011-03-29 2014-02-26 Geron Corp Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
EP2691512A1 (en) * 2011-03-29 2014-02-05 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
US9395354B2 (en) 2011-07-21 2016-07-19 The Board Of Trustees Of The Leland Stanford Junior University Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof
US10597637B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
WO2017172086A1 (en) * 2016-02-19 2017-10-05 Leung Chuen Yan Genetic markers for engraftment of human cardiac ventricular progenitor cells
US11725244B2 (en) 2016-02-19 2023-08-15 Procella Therapeutics Ab Genetic markers for engraftment of human cardiac ventricular progenitor cells
US10612094B2 (en) 2016-02-19 2020-04-07 Procella Therapeutics Ab Genetic markers for engraftment of human cardiac ventricular progenitor cells
EP4269566A3 (en) * 2016-02-19 2024-01-10 Procella Therapeutics AB Genetic markers for engraftment of human cardiac ventricular progenitor cells
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
US11401508B2 (en) 2016-11-29 2022-08-02 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
US11186820B2 (en) 2017-08-23 2021-11-30 Procella Therapeutics Ab Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells

Also Published As

Publication number Publication date
AU2007357127A1 (en) 2009-02-05
US20160320409A1 (en) 2016-11-03
IL203575A (en) 2016-02-29
GB201002084D0 (en) 2010-03-24
GB2465502A (en) 2010-05-26
GB2465502B (en) 2013-06-26
US20100247493A1 (en) 2010-09-30
WO2009017460A8 (en) 2009-07-23
AU2007357127B2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
AU2007357127B2 (en) Method for identifying and selecting cardiomyocytes
EP2691512B1 (en) Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
Mummery et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview
KR101529317B1 (en) Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
Zweigerdt et al. Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies
US8470595B2 (en) Mesenchymal stem cell and method for production thereof
Burridge et al. Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes
Xu Differentiation and enrichment of cardiomyocytes from human pluripotent stem cells
EP2273996A2 (en) Human cardiovascular progenitor cells
JP6097076B2 (en) Progeny of differentiated pluripotent stem cells that exclude excluded phenotypes
US20120301445A1 (en) Tools for isolating and following cardiovascular progenitor cells
WO2013063305A2 (en) Directed cardiomyocyte differentiation of stem cells
US11390851B2 (en) Process for generation, identification and isolation of human pluripotent stem cell-derived cardiomyocytes and cardiomyocyte subpopulations
Månsson-Broberg et al. Wnt/β-catenin stimulation and laminins support cardiovascular cell progenitor expansion from human fetal cardiac mesenchymal stromal cells
Ibarra-Ibarra et al. Improved efficiency of cardiomyocyte-like cell differentiation from rat adipose tissue-derived mesenchymal stem cells with a directed differentiation protocol
Laposa Stem cells for drug screening
Aubin et al. Osteoblast lineage in experimental animals
JP2021151269A (en) Production method of pluripotent stem cell spheroid, method for expressing pluripotent stem cell marker and pluripotent stem cell spheroid
GB2496322A (en) Method for identifying and selecting cardiomyocytes
SG183071A1 (en) Method for identifying and selecting cardiomyocytes
Chen et al. Common marmoset embryonic stem cell can differentiate into cardiomyocytes
Xu et al. Perspective from the heart: The potential of human pluripotent stem cell‐derived cardiomyocytes
CA3234329A1 (en) Method for separating pituitary cells and hypothalamic cells using cell surface marker
WO2024073776A1 (en) Methods for the production of cardiac fibroblasts
RU2505602C1 (en) Method for obtaining resident stem cells of mammal heart from myocard sample

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794240

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 203575

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12671274

Country of ref document: US

Ref document number: 2007357127

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 1002084

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20070731

WWE Wipo information: entry into national phase

Ref document number: 1002084.0

Country of ref document: GB

ENP Entry into the national phase

Ref document number: 2007357127

Country of ref document: AU

Date of ref document: 20070731

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 07794240

Country of ref document: EP

Kind code of ref document: A1